Sex-specific differences in recurrence and progression following cytostatic intravesical chemotherapy for non-muscle invasive urothelial bladder cancer (NMIBC)
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.This study found no significant gender differences in non-muscle-invasive bladder cancer (NMIBC) outcomes after intravesical chemotherapy. However, limited data and underrepresentation of women necessitate further gender-focused research for equitable care.
Area Of Science
- Urology
- Oncology
- Clinical Research
Background
- Non-muscle-invasive bladder cancer (NMIBC) treatment often involves intravesical chemotherapy.
- Understanding potential gender-specific differences in treatment outcomes is crucial for personalized medicine.
Purpose Of The Study
- To systematically analyze gender-specific differences in survival outcomes (RFS, PFS, CSS, OS) for NMIBC patients undergoing intravesical chemotherapy.
- To assess gender-specific differences in adverse events and quality of life (QoL) as secondary objectives.
Main Methods
- A systematic review and meta-analysis of 12 studies (1,527 patients) published between 1976 and 2024.
- PRISMA guidelines were followed, with data analyzed using random-effects models, focusing on gender as a primary variable.
- Risk of bias was assessed using ROBINS-I or RoB2 tools.
Main Results
- No statistically significant gender-specific differences were found in recurrence-free survival (RFS) or progression-free survival (PFS).
- Data for cancer-specific survival (CSS) and overall survival (OS) were insufficient for robust conclusions.
- Gender was not identified as a significant risk factor for recurrence or progression in the included studies; adverse events and QoL data were underreported.
Conclusions
- Current evidence suggests no significant gender-based differences in NMIBC outcomes with intravesical chemotherapy.
- Limitations include a small study number, underrepresentation of women, and inconsistent outcome reporting.
- Future research should prioritize gender-focused analyses and investigate molecular/genetic factors for precision medicine and equitable care.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...